Posted: February 4, 2021 Enlarge Image Enlarge Image Dr. Jill Biden, Ph.D., First Lady of the United States, joined NCI leaders and staff for a special virtual event marking World Cancer Day, February 4. Among the progress highlighted was the work of the NCI Community Oncology Research Program (NCORP) in bringing clinical trials to diverse […]
In 2009, during a routine mammogram, a small mass was discovered in Mary Elise Samson’s left breast. “I was surprised when they told me they found a lump,” recalled Mary Elise, a retired teacher living in Ste. Genevieve. “Because of its size and location, I couldn’t feel it during my self-exam.” News No One Wants […]
New findings from the groundbreaking Trial Assigning Individualized Options for Treatment (Rx), or TAILORx trial, show no benefit from chemotherapy for 70 percent of women with the most common type of breast cancer. The study found that for women with hormone receptor (HR)-positive, HER2-negative, axillary lymph node-negative breast cancer, treatment with chemotherapy and hormone therapy […]
People diagnosed with cancer gained 3.34 million years of life thanks to cancer clinical trials run by SWOG and supported with public funds, according to new study results to be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO), the world’s largest clinical cancer research meeting.
At the ASCO 2017 Meeting, Heartland investigators were proud to hear presentations and discussions about studies in which our patients participated and in which our doctors and staff played a significant role in generating new discoveries.
This precision medicine trial continues with a new study entry process that casts a wider net for patients through routine genomic testing. Within Heartland, we had 164 continue toward the 6,000 patient goal that was reached two years early.
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
Bone involvement in metastatic cancer is a common clini-cal problem. The US Food and Drug Administration ap-proved zoledronic acid, a third-generation aminobis-phosphonate, for the treatment of patients with multiple myeloma and bone metastases from solid tumors.
Nausea and disturbed sleep as predictors of cancer-related fatigue in breast cancer patients: a multicenter NCORP study
Purpose Cancer-related fatigue (CRF) is a prevalent and distressing side effect of cancer and its treatment that remains inadequately understood and poorly managed. A better understanding of the factors contributing to CRF could result in more effective strategies for the prevention and treatment of CRF. The objectives of this study were to examine the prevalence, […]
Dental health status and patient-reported outcomes at baseline in patients participating in the osteonecrosis of the jaw registry study, SWOG S0702
Purpose SWOG S0702 was a cohort study of patients with cancer with bone metastases due to any cancer. Using baseline data from S0702, this report characterizes the oral health and oral health-related quality of life (OHRQoL) of patients with advanced cancer. Methods S0702 case report forms captured dental assessment and patient-reported outcome (PRO) data. This […]
INTRODUCTION Small cell lung cancer (SCLC) accounts for 12% of all cases of lung cancer in the United States.1 SCLC is characterized by its rapid doubling time and the early development of metastatic disease, and for decades, combination chemotherapy, con-sisting of a platinum agent and the topoisomerase II inhibitor etoposide, has been the mainstay of […]